Poyun Biomedical Technology

Poyun Biomedical Technology refers to the Suzhou operating entity of Cloudbreak Pharma, an ophthalmology-focused biotech developing therapies for diseases of the front and back of the eye. The company is building a pipeline of mostly topical ocular therapies spanning pterygium, juvenile myopia, vascularized pinguecula, meibomian gland dysfunction-associated dry eye disease, diabetic macular edema, presbyopia, and glaucoma filtration surgery. Its lead program CBT-001 is a multi-kinase inhibitor eye drop in Phase 3 for pterygium, and CBT-009 has also been described by the company as having reached Phase 3 planning/progression in the U.S. for juvenile myopia. Cloudbreak highlights internal discovery and development capabilities, including its SFA+ formulation platform and ophthalmic drug-delivery expertise. The broader pipeline includes both small-molecule ocular drugs and an antibody-drug-synergism conjugate program.